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Merkel cell carcinoma (MCC) is an aggressive cutaneous malignancy linked to a contributory virus (Merkel cell
polyomavirus). Multiple epidemiologic studies have established an increased incidence of MCC among persons
with systemic immune suppression. Several forms of immune suppression are associated with increased MCC
incidence, including hematologic malignancies, HIV/AIDS, and immunosuppressive medications for autoimmune
disease or transplant. Indeed, immune-suppressed individuals represent B10% of MCC patients, a significant
overrepresentation relative to the general population. We hypothesized that immune-suppressed patients may
have a poorer MCC-specific prognosis and examined a cohort of 471 patients with a combined follow-up of 1,427
years (median 2.1 years). Immune-suppressed patients (n¼ 41) demonstrated reduced MCC-specific survival (40%
at 3 years) compared with patients with no known systemic immune suppression (n¼ 430; 74% MCC-specific
survival at 3 years). By competing risk regression analysis, immune suppression was a stage-independent
predictor of worsened MCC-specific survival (hazard ratio 3.8, Po0.01). Thus, immune-suppressed individuals
have both an increased chance of developing MCC and poorer MCC-specific survival. It may be appropriate to
follow these higher-risk individuals more closely, and, when clinically feasible, there may be a benefit of
diminishing iatrogenic systemic immune suppression.
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INTRODUCTION
Merkel cell carcinoma (MCC) is a neuroendocrine skin cancer
with a prognosis poorer than that of melanoma. In 2008, a
polyomavirus (Merkel cell polyomavirus) was reported to be a
likely causative agent for the majority of MCCs (Feng et al.,
2008); this has subsequently been well established by multiple
international groups (Foulongne et al., 2008; Becker et al.,
2009; Garneski et al., 2009). Most MCC tumors depend on
persistent expression of viral T-antigen oncoproteins, (Shuda
et al., 2009; Houben et al., 2010; Shuda et al., 2011) which
are targets for the cellular (Iyer et al., 2011) and humoral
immune system (Paulson et al., 2010).
It has been well established that immune suppression is
associated with increased risk of developing MCC. Indeed,
immune-suppressed individuals make up B10% of the MCC
patient population (Heath et al., 2008), and it is this link that
led to the search for, and the eventual discovery of, Merkel
cell polyomavirus (Arora et al., 2012). Multiple forms of
systemic immune suppression have been linked with an
increased incidence of MCC, including chronic lymphocytic
leukemia and other hematologic malignancies (Heath et al.,
2008; Brewer et al., 2012), HIV/AIDS (particularly before the
widespread adoption of effective antiretrovirals) (Engels et al.,
2002), solid organ transplant (Penn and First, 1999), and
autoimmune disease (with associated treatment regimens)
(Hemminki et al., 2012).
Conversely, and consistent with a role for antiviral immune
responses in protecting against MCC progression, CD8þ and
CD3þ intratumoral lymphocyte responses have been found
to be associated with improved MCC outcomes (Paulson et al.,
2011; Sihto et al., 2012). In both of these studies, patients with
robust lymphocyte infiltration into the tumor make up a
minority of patients but exhibit outstanding MCC-specific
survival.
One form of systemic immune suppression, chronic lym-
phocytic leukemia, has recently been associated with reduced
MCC survival in a national cancer registry (Brewer et al.,
2012). However, to our knowledge, the effect of chronic
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immune suppression more broadly on MCC outcomes has not
been examined. We hypothesized that systemic immune
suppression would be associated with worsened MCC-
specific survival in a stage-independent manner.
RESULTS
Frequency and distribution of systemic immune suppression
among MCC patients
Of the 471 patients with MCC from the United States, a total
of 41 (8.7%) had clinically recognized systemic immune
suppression. Immune-suppressed patients were similar to
those without immune suppression in terms of age at diagnosis
and stage of disease at presentation (Table 1), but differed in
terms of gender distribution with immune-suppressed indivi-
duals more likely to be male (80% vs. 59%; Po0.01). Multiple
forms of systemic immune suppression were represented
including chronic lymphocytic leukemia (n¼16; 3% of
MCC patient cohort), other hematologic malignancies (n¼5;
1%), HIV/AIDS (n¼5; 1%), and long-term immunosuppres-
sive medication regimens used for autoimmune disease (n¼3;
1%) or solid organ transplant (n¼ 12; 3%).
Persons with systemic immune suppression and MCC have
diminished overall survival
A combined 1,427 years of follow-up was available for the
471 patients with MCC (median 2.1 years). Patients with MCC
and systemic immune suppression had worsened overall
survival as compared with patients with MCC and no systemic
immune suppression (hazard ratio 2.1; Po0.01). Three-year
overall survival was 33% in the immune-suppressed group
and 59% in the comparison group.
Persons with systemic immune suppression have worsened
MCC-specific survival
We hypothesized that individuals with systemic immune
suppression would have worsened MCC-specific survival as
compared with individuals without systemic immune suppres-
sion because of failed immune surveillance of the cancer. We
also reasoned that the groups were likely to have different
rates of non-MCC death. Therefore, to account for possible
differences in the death rate from other causes between the
two groups, we performed competing risk regression analysis
where only deaths from MCC were considered to be events,
and deaths from other causes (including non-MCC deaths
related to the immune suppression process) were considered
to be competing events.
Immune-suppressed individuals (n¼41) had statistically
significantly worsened MCC-specific survival as compared
with individuals without immune suppression (n¼430)
(hazard ratio 3.0; 95% confidence interval 1.8–4.8; Po0.01;
Table 2). Furthermore, this difference was clinically appreci-
able, with immune-suppressed patients having a 3-year
survival proportion that was approximately half than that of
the nonimmune-suppressed patients (40% vs. 74%; Po0.05
for point comparison; Figure 1).
Our patient population represents a nonoverlapping mixture
of patients enrolled either as individuals (n¼228) or as part of
records review in institutional sets (n¼243). To ensure that
our results were similar between the two categories of
patients, we looked at each subgroup independently and
found that in each case immune suppression was a significant
predictor of worsened outcome (records based enrollment:
hazard ratio 2.5; P¼ 0.01) (individual enrollment: hazard ratio
4.0; Po0.01).
Table 1. Demographics
Nonimmune
suppressed
(n¼ 430)
Immune
suppressed
(n¼41)
Characteristic N Percent (%) N Percent (%) P-value
Stage at diagnosis
Local 242 56 23 56 0.94 (NS)
Regional 147 34 15 37
Distant 41 10 3 7
Sex
Female 177 41 8 20 o0.01
Male 253 59 33 80
Age at diagnosis
o65 Years 127 30 17 41 0.16 (NS)
X65 Years 303 70 24 59
Abbreviation: NS, nonsignificant.
Immune-suppressed and nonimmune-suppressed patient groups were
similar in terms of stage at diagnosis and patient age but differed in their
gender distributions, with immune-suppressed patients being more likely to
be male.
Age quartiles for the 25th, 50th, and 75th percentile were 63, 72, and 79
years for the nonimmune-suppressed group and 58, 67, and 77 years for
the immune-suppressed group, respectively. Comparisons were made using
the Fisher’s exact test. N¼ 471.
Table 2. Multivariate competing risk regression
analyses demonstrate immune suppression is an
independent predictor of poor Merkel cell carcinoma–
specific survival
Univariate Multivariate
Characteristic HR 95% CI HR 95% CI
Extent of disease at presentation
Regional (vs. local) 3.41 2.3–5.0 3.51 2.3–5.2
Distant (vs. local) 6.31 3.6–10.8 7.41 4.2–13.1
Sex
Female (vs. male) 0.8 0.6–1.2 0.9 0.6–1.4
Age at diagnosis
Age (per year older) 1.00 0.98–1.01 1.00 0.99–1.02
Systemic immune suppression
Immunosuppressed (vs. non
immunosuppressed)
3.01 1.8–4.8 3.81 2.2–6.4
Abbreviations: CI, confidence interval; HR, hazard ratio.
Left column: univariate analyses considering each listed variable. Right
column: multivariate analysis including all listed variables.
1Indicates Po0.05. N¼471.
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Immune suppression is a stage-independent predictor of
diminished MCC-specific survival
We observed significantly reduced MCC-specific survival
among immune-suppressed patients at all stages of
presentation (Figure 1). To formally test whether immune
suppression represents an independent predictor of MCC
outcome, we performed multivariate competing risk regres-
sion analysis accounting for stage at presentation (local–
regional–distant stage), age at diagnosis, and gender in
addition to immune suppression (Table 2). Immune suppres-
sion represented a significant independent predictor of wor-
sened MCC-specific survival (hazard ratio 3.8; 95% CI 2.2–
6.4; Po0.01).
We initially performed our analysis using local–regional–
distant stage to minimize the number of variables in the
model. However, we repeated this analysis using the current
American Joint Committee on Cancer 7th Edition staging
(Lemos et al., 2010) instead to determine whether immune
suppression adds information to current consensus staging. Of
the 471 patients, 395 patients had sufficient information to
determine American Joint Committee on Cancer substage at
presentation. Again, immune suppression was a significant
stage-independent predictor of poorer MCC-specific outcome
(hazard ratio 4.2; 95% CI 2.4–7.4; Po0.01; Supplementary
Table S1 online). We performed a third analysis also including
lymphovascular invasion status in the model (data available
for 149 patients); results were similar and remained significant
(hazard ratio 8.9; 95% CI 3.8–21.2; Po0.01).
DISCUSSION
MCC is an aggressive skin cancer. At least 75% of MCC cases
have a viral etiology. It has been well established that multiple
forms of immune suppression (including HIV, hematologic
malignancies, and immunosuppressive medications) are
linked with an increased risk of developing MCC (Quaglino
et al., 1997; Penn and First, 1999; Engels et al., 2002; Heath
et al., 2008; Lanoy et al., 2009; Lanoy and Engels, 2010;
Hemminki et al., 2012; Sihto et al., 2012). However, the effect
of systemic immune suppression on MCC prognosis has not
been well studied.
We find that systemic immune suppression is a stage-
independent predictor of worsened survival among patients
with MCC. To account for possible differences in overall health
between immune-suppressed and nonimmune-suppressed
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Figure 1. Merkel cell carcinoma (MCC) survival and immune suppression. Large graph: individuals with immune suppression (n¼ 41) had significantly worsened
MCC-specific survival as compared with those without systemic immune suppression (n¼ 430) on univariate (hazard ratio 3.0; Po0.01) and multivariate (hazard
ratio 3.8; Po0.01) competing risk regression analyses (Table 2). Numbers at risk at 1, 3, 5, and 7 years indicated below. Small graphs: effects of immune
suppression persisted across stage at presentation.
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individuals, we performed the competing risk regression
analysis specifically considering the cause of death. Notably,
3-year MCC-specific survival was nearly twice as good in the
nonimmune-suppressed group, suggesting systemic immune
suppression is of significant clinical importance.
Individuals with systemic immune suppression have been
found to be at an increased risk of developing other skin
cancers, including squamous cell carcinoma (SCC), basal cell
carcinoma, and melanoma. SCC incidence is at least 50-fold
increased among solid organ transplant recipients (Moloney
et al., 2006) and transplant patients with metastatic disease
have a poorer SCC prognosis as compared with immune-
competent patients (Martinez et al., 2003). Furthermore,
melanoma has been associated with poorer outcomes
among immunocompromised populations as compared with
healthy populations (Matin et al., 2008), and this melanoma-
associated mortality significantly increases the total mortality
of the immune-suppressed patients (Alam et al., 2011).
Combined with our findings regarding MCC, these data
highlight the importance of carefully following the skin of
immune-suppressed individuals and having a low threshold
for biopsy of suspicious lesions.
Limitations
Our study had several limitations. Many of the patients were
enrolled through referral to tertiary centers, thus suggesting a
source of ascertainment bias. To mitigate this as much as
possible, we limited the inclusion of patients who presented
within 180 days of diagnosis. Given the variable nature of
human disease, we were unable to control for the relative
degree of immune suppression between various immune-
suppressed patients. Finally, although MCC is increasing in
incidence it remains an uncommon disease. Although our
study size of 471 is large for MCC, we still did not have a
sufficient number of immune-suppressed patients to determine
the relative impact of each of the various forms of immune
suppression on survival.
Immune suppression is associated with both increased MCC
incidence and worsened MCC outcome. Conversely, strong
intratumoral immune responses are associated with improved
MCC survival (Paulson et al., 2011; Sihto et al., 2012). Given
these associations and the known viral immune targets in
MCC, immune therapy holds significant promise for the future
treatment of MCC. At this time, in the treatment of patients
with immune suppression and MCC, it would appear prudent
to follow these higher-risk patients very closely and also
consider reducing or modifying iatrogenic immune suppres-
sion whenever feasible, given the clinical context.
MATERIALS AND METHODS
Patient enrollment
All studies were approved by the institutional review board (FHCRC
IRB# 6585), conducted in accordance with the Declaration of
Helsinki Principles, and written informed patient consent was
obtained. All MCC patients in the FHCRC repository of data and
specimens were considered for inclusion and all were enrolled in
the United States. Enrollment criteria included (all must be present): a
diagnosis of MCC confirmed by two pathologists, the presence of
follow-up information, known stage at diagnosis (local–regional–
distant), known age at diagnosis, known gender, and known
immune suppression status. Patients in the repository enroll in one
of the two approaches: either as individuals (through our tertiary
referral clinic and the internet) or through records review as part of a
patient set from one of the several institutions (including a 186 patient
cohort from Kaiser Permanente, a large integrated health care delivery
system in Northern California). Patients were represented only
once. Patients enrolling as individuals after 180 days of diagnosis
were eliminated to reduce ascertainment bias. A total of 471
unique patients with MCC met all criteria (243 from institution
cohorts and 228 as individuals); demographics are described in
Table 1.
Statistical analyses
Demographic and stage information were compared between
immune-suppressed and nonimmune-suppressed persons using the
Fisher’s exact test. Overall survival analyses (considering deaths from
any cause to be events) were performed using the Cox regression.
Disease-specific survival analyses were performed with competing
risk regression. For competing risk regression, deaths from MCC were
considered to be events (n¼ 126), deaths from other causes were
considered to be competing events (n¼ 75), deaths from unknown
causes were censored on the day of death (n¼ 31), and living patients
were censored on the date of last follow-up (n¼ 239). Kaplan–Meier
curves were generated to visually compare survival between groups.
Statistical analyses were performed using the Stata version 11.0
software (College Station, TX) for Macintosh. A P-value of 0.05 was
considered to be the cutpoint for statistical significance.
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